Highest Paying Dividend Stocks to Buy Now

TLDR

• Verizon leads the Dow with a 6.8% yield but faces slow dividend growth of 2% annually and has a new CEO with uncertain plans
• Chevron offers 4.6% yield with 37 consecutive years of dividend increases, supported by an integrated business model and strong balance sheet
• Merck provides 3.4% yield and trades 25% below 2024 highs while managing patent cliff concerns over the coming years
• Johnson & Johnson delivers 3.0% yield with 62 years of consecutive dividend increases and trades at $206 with analyst targets of $227
• Coca-Cola yields 2.9% with 63 years of dividend growth, backed by AI strategy and emerging market expansion

Dividend stocks continue to attract investors seeking steady income as markets respond to Federal Reserve rate decisions. The Dow Jones Industrial Average contains several companies with yields ranging from 2.9% to 6.8%. These stocks span multiple sectors including telecom, energy, healthcare, consumer staples, and real estate.

Investment experts warn that high yields alone do not guarantee strong returns. Investors need to understand the business fundamentals behind each dividend payment. They also need to ensure these stocks match their portfolio goals and risk tolerance.

Verizon Communications

Verizon offers the highest yield in the Dow at 6.8%. The telecom giant benefits from steady customer retention in its core business. Most subscribers stick with their provider for years, creating predictable revenue streams.

Verizon Communications Inc., VZ

The company carries substantial debt due to capital-intensive network operations. These networks require constant upgrades to remain competitive. Verizon’s dividend growth has averaged just 2% annually over the past decade.

This growth rate trails historical inflation, reducing the dividend’s buying power over time. The company recently appointed a new CEO to improve growth prospects. New leadership brings both opportunity and risk, as management transitions sometimes result in dividend cuts.

The stock currently trades around $41. Twelve analysts rate it a “Buy” with an average price target of $48.50. Scotiabank cites subscriber additions as a positive factor while maintaining a “Sector Perform” rating.

Chevron Corporation

Chevron provides a 4.6% yield backed by 37 consecutive years of dividend increases. This streak stands out in the volatile energy sector. The company operates across upstream production, midstream pipelines, and downstream refining.

Chevron Corporation, CVX

This integrated model helps smooth out industry cycles. Each segment performs differently during various market conditions. Chevron maintains a debt-to-equity ratio of just 0.22.

The strong balance sheet gives management flexibility during downturns. The company can borrow to fund operations and dividends when oil prices fall. When prices recover, Chevron reduces leverage in preparation for the next cycle.

The stock trades near $152 per share with a 4.2% yield. Seventeen analysts rate it a “Buy” with an average target of $172. HSBC set a $169 target highlighting share buyback programs while Wells Fargo maintains a $196 target.

Merck & Company

Merck yields 3.4% and ranks among the world’s largest pharmaceutical companies. The stock trades around $100 after climbing 41% over six months. It remains about 25% below its 2024 peak levels.

Merck & Co., Inc., MRK

The company faces patent expirations on key drugs in coming years. These patent cliffs can hurt revenues and earnings when blockbuster drugs lose protection. Drug companies typically replace these losses through new drug development or acquisitions.

Merck’s dividend payout ratio sits around 45%. This leaves room to maintain payments during the patent transition period. Keytruda generates over $25 billion in annual sales for the company.

Thirteen analysts rate the stock a “Buy” with a $107 average target. J.P. Morgan set a $120 price target based on HIV pipeline developments. Goldman Sachs also raised its target to $120 reflecting improved valuation metrics.

Johnson & Johnson

Johnson & Johnson yields 3.0% with 62 consecutive years of dividend increases. The healthcare giant trades around $206, up 14% year-to-date. Its oncology products including Keytruda-related treatments drive current growth.

The medical device division adds revenue stability to the overall business. Fifteen analysts rate the stock a “Buy” with an average price target of $198. Guggenheim analyst Vamil Divan recently raised his target to $227.

Barclays maintains an “Equal-Weight” rating at $197. The firm projects earnings per share of $10.86 in 2025.

Coca-Cola Company

Coca-Cola delivers a 2.9% yield backed by 63 years of dividend growth. The stock trades near $73 with gains from emerging markets. Thirteen analysts give the stock a “Strong Buy” rating.

The average price target sits at $78, representing a 7% potential increase. UBS holds an $82 target following discussions about the company’s AI strategy. Bank of America set an $80 price target pointing to a 25% increase in net income.

Realty Income Corporation

Realty Income yields 5.0% with monthly dividend payments. The real estate investment trust trades around $59 with a portfolio of 15,500 properties. Thirteen analysts give it a “Hold” rating with a $62 target.

Barclays set a $64 price target noting $6 billion in planned 2025 investments. The REIT focuses on retail properties with long-term leases designed to withstand e-commerce pressure.

The post Highest Paying Dividend Stocks to Buy Now appeared first on Blockonomi.